Overview

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Status:
Recruiting

Trial end date:
2026-07-14

Target enrollment:

Participant gender:

Summary

Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Midazolam